405 related articles for article (PubMed ID: 12154101)
1. Mineralocorticoid and angiotensin receptor antagonism during hyperaldosteronemia.
Mihailidou AS; Mardini M; Funder JW; Raison M
Hypertension; 2002 Aug; 40(2):124-9. PubMed ID: 12154101
[TBL] [Abstract][Full Text] [Related]
2. Hyperaldosteronemia in rabbits inhibits the cardiac sarcolemmal Na(+)-K(+) pump.
Mihailidou AS; Bundgaard H; Mardini M; Hansen PS; Kjeldsen K; Rasmussen HH
Circ Res; 2000 Jan 7-21; 86(1):37-42. PubMed ID: 10625303
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats.
Minas JN; Thorwald MA; Conte D; Vázquez-Medina JP; Nishiyama A; Ortiz RM
Clin Exp Pharmacol Physiol; 2015 Nov; 42(11):1178-88. PubMed ID: 26234762
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T
Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023
[TBL] [Abstract][Full Text] [Related]
5. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats.
Nagata K; Obata K; Xu J; Ichihara S; Noda A; Kimata H; Kato T; Izawa H; Murohara T; Yokota M
Hypertension; 2006 Apr; 47(4):656-64. PubMed ID: 16505208
[TBL] [Abstract][Full Text] [Related]
6. The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism.
Eudy RJ; Sahasrabudhe V; Sweeney K; Tugnait M; King-Ahmad A; Near K; Loria P; Banker ME; Piotrowski DW; Boustany-Kari CM
J Transl Med; 2011 Oct; 9():180. PubMed ID: 22017794
[TBL] [Abstract][Full Text] [Related]
7. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
[TBL] [Abstract][Full Text] [Related]
8. Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist.
Takeda Y
Hypertens Res; 2004 Nov; 27(11):781-9. PubMed ID: 15824460
[TBL] [Abstract][Full Text] [Related]
9. Non-genomic effects of spironolactone and eplerenone in cardiomyocytes of neonatal Wistar rats: do they evoke cardioprotective pathways?
Hermidorff MM; Faria Gde O; Amâncio Gde C; de Assis LV; Isoldi MC
Biochem Cell Biol; 2015 Feb; 93(1):83-93. PubMed ID: 25488178
[TBL] [Abstract][Full Text] [Related]
10. Alloxan-induced diabetes reduces sarcolemmal Na+-K+ pump function in rabbit ventricular myocytes.
Hansen PS; Clarke RJ; Buhagiar KA; Hamilton E; Garcia A; White C; Rasmussen HH
Am J Physiol Cell Physiol; 2007 Mar; 292(3):C1070-7. PubMed ID: 17020934
[TBL] [Abstract][Full Text] [Related]
11. Na+ influx and Na(+)-K+ pump activation during short-term exposure of cardiac myocytes to aldosterone.
Mihailidou AS; Buhagiar KA; Rasmussen HH
Am J Physiol; 1998 Jan; 274(1):C175-81. PubMed ID: 9458726
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
Hu X; Li S; McMahon EG; Lala DS; Rudolph AE
Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407
[TBL] [Abstract][Full Text] [Related]
13. Rapid, nongenomic effects of aldosterone in the heart mediated by epsilon protein kinase C.
Mihailidou AS; Mardini M; Funder JW
Endocrinology; 2004 Feb; 145(2):773-80. PubMed ID: 14605011
[TBL] [Abstract][Full Text] [Related]
14. Nongenomic effect of aldosterone on Na+,K+-adenosine triphosphatase in arterial vessels.
Alzamora R; Marusic ET; Gonzalez M; Michea L
Endocrinology; 2003 Apr; 144(4):1266-72. PubMed ID: 12639909
[TBL] [Abstract][Full Text] [Related]
15. Aldosterone receptor antagonists and cardiovascular disease: do we need a change of the guard?
Jewell CW; Watson LE; Mock J; Dostal DE
Cardiovasc Hematol Agents Med Chem; 2006 Apr; 4(2):129-53. PubMed ID: 16611048
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of aldosterone blockade.
Weber MA
Am Heart J; 2002 Nov; 144(5 Suppl):S12-8. PubMed ID: 12422136
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.
Flack JM; Oparil S; Pratt JH; Roniker B; Garthwaite S; Kleiman JH; Yang Y; Krause SL; Workman D; Saunders E
J Am Coll Cardiol; 2003 Apr; 41(7):1148-55. PubMed ID: 12679215
[TBL] [Abstract][Full Text] [Related]
18. Eplerenone: a selective aldosterone receptor antagonist (SARA).
Delyani JA; Rocha R; Cook CS; Tobert DS; Levin S; Roniker B; Workman DL; Sing YL; Whelihan B
Cardiovasc Drug Rev; 2001; 19(3):185-200. PubMed ID: 11607037
[TBL] [Abstract][Full Text] [Related]
19. Mineralocorticoid Receptor Blockade Improves Insulin Sensitivity in the Rat Heart and a Possible Molecular Mechanism.
Wang M; Li Y; Zhou K; Zhang G; Wang Y; Liu T; Zhang Y; Guo A; An Y
Cell Physiol Biochem; 2016; 39(3):860-70. PubMed ID: 27497962
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms for nongenomic and genomic effects of aldosterone on Na+/H+ exchange in vascular smooth muscle cells.
Miyata Y; Muto S; Kusano E
J Hypertens; 2005 Dec; 23(12):2237-50. PubMed ID: 16269966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
